Is Cathie Wood Invested in BNGO? As of the time of this writing, it does not appear that Cathie Wood or ARK are invested in Bionano Genomics. The firm’s genomics and biomedical ETF, ARKG, currently contains 52 individual holdings.
Similarly, Who owns Bionano genomics?
Top 10 Owners of Bionano Genomics Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| BlackRock Fund Advisors | 5.74% | 16,609,007 |
| The Vanguard Group, Inc. | 4.86% | 14,064,639 |
| SSgA Funds Management, Inc. | 2.49% | 7,198,880 |
| Geode Capital Management LLC | 1.63% | 4,714,883 |
Is BNGO in ARKG? Ark Invest’s Chapter in the BNGO Stock Story
The fund manager has sent some public praise BNGO’s way. Ark even has a special portfolio — Ark Genomic Revolution ETF (NYSEARCA:ARKG) — for just that sort of stock material. Thus, it was only a matter of time before the stock caught on, right?
Thereof, Is BNGO waiting for FDA approval?
The Food and Drug Administration has not yet approved the device for use as a medical diagnostic tool in the U.S. However, healthcare entities can still use it for research purposes. The lack of FDA approval has also not hindered sales of the Saphyr in other countries.
What does Bionano genomics do?
Bionano Genomics, Inc. provides a platform to analyze the long segments of genomic DNA and other biomolecules structural variations. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents.
What is BNGO target price?
The 4 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 7.50, with a high estimate of 14.00 and a low estimate of 6.00. The median estimate represents a +258.85% increase from the last price of 2.09.
Where is BNGO based?
The company was founded in 2003 and is headquartered in San Diego, California.
What institutions are buying NIO?
Largest shareholders include Baillie Gifford & Co, BlackRock Inc., Vanguard Group Inc, State Street Corp, VWIGX – Vanguard International Growth Fund Investor Shares, Susquehanna International Group, Llp, Goldman Sachs Group Inc, Citadel Advisors Llc, VEIEX – Vanguard Emerging Markets Stock Index Fund Investor Shares, …
Is BNGO a pump and dump?
BNGO stock has suffered at the hands of a Ritalin-using pump and dump scheme making waves in 2021.
Is it too late to buy AMC shares?
So, is it too late to purchase AMC stock? The price after a short squeeze eventually fall back down and level out, but this will take time. With AMC stock trading below $100, now could be the perfect time to buy.
Why does Bionano have tremendous potential?
The Bottom Line on BNGO Stock
Saphyr allows diseases to be more effectively researched than competing products. And, it is tremendously cheaper than other genomic-mapping tools. But it could also more successfully determine patients more susceptible to severe cases of viruses. These viruses include Covid-19.
What sector is BNGO stock?
Key Data
| Label | Value |
|---|---|
| Sector | Capital Goods |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| 1 Year Target | $11.00 |
| Today’s High/Low | $2.77/$2.57 |
What sector is BNGO in?
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space.
What does BNGO company do?
Company Description
The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics.
How high does IDEX go?
IDEX stock hit a 2022 high of $1.44 in early January and a low of $0.87 later in the same month. In 2021 its stock price ranged from 88 cents to $5.53. In an interview with Capital.com, Vinod Jain, senior analyst at Aite-Novarica Group, said “the stock could see more volatility due to its current price point”.
What kind of company is Bionano genomics?
Bionano Genomics, Inc. provides a platform to analyze the long segments of genomic DNA and other biomolecules structural variations. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents.
How many employees does BNGO have?
Compare BNGO With Other Stocks
| Bionano Genomics Annual Number of Employees | |
|---|---|
| 2020 | 147 |
| 2019 | 97 |
| 2018 | 77 |
| 2017 | 65 |
Who owns most of NIO?
Top 10 Owners of NIO Inc
| Stockholder | Stake | Total value ($) |
|---|---|---|
| BlackRock Fund Advisors | 2.99% | 915,727,477 |
| The Vanguard Group, Inc. | 2.76% | 844,953,786 |
| SSgA Funds Management, Inc. | 2.45% | 751,155,776 |
| Goldman Sachs & Co. LLC (Private … | 1.73% | 529,951,450 |
Does Vanguard own NIO stock?
The top institutional shareholders of NIO are Originalwish Ltd., Tencent Holdings Ltd., Baillie Gifford & Co., BlackRock Inc. (BLK), and Vanguard Group Inc. Because NIO is a foreign company, it doesn’t file Form 4s for its individual insider shareholders.
What percent of NIO is public?
Public Company Ownership
Public companies currently own 8.5% of NIO stock. It’s hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it’s worth watching this space for changes in ownership.
Join TheMoney.co community and don’t forget to share this post !
